


PRODUCT INFORMATION



Marbofloxacin

Item No. 24174

CAS Registry No.: 115550-35-1
Formal Name: 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid
MF: C₁₇H₁₉FN₄O₄
FW: 362.4
Purity: ≥98%
UV/Vis.: λ_{max}: 217, 304 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Marbofloxacin is supplied as a crystalline solid. A stock solution may be made by dissolving the marbofloxacin in the solvent of choice, which should be purged with an inert gas. Marbofloxacin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of marbofloxacin in these solvents is approximately 1, 25, and 30 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of marbofloxacin can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of marbofloxacin in PBS, pH 7.2, is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Marbofloxacin is a fluoroquinolone antibiotic that is active against *P. multocida* *in vitro* (MIC = 0.016 µg/ml).¹ It exhibits broad-spectrum antibacterial activity mediated by the inhibition of DNA gyrase, with MIC values ranging from 0.016 to 0.4 and 0.19 to 1.7 µg/ml against various Gram-negative and Gram-positive bacterial isolates, respectively.² Intramuscular administration of marbofloxacin (2 mg/kg) after infection prevents the formation of pulmonary lesions in a bovine calf model of *M. haemolytica* A1 pneumonia.³ Oral administration of marbofloxacin (2 mg/kg per day) also exhibits antileishmanial activity in a canine model of leishmaniasis, decreasing parasitic load by 72%.⁴ Formulations containing marbofloxacin have been used in the veterinary treatment of bacterial infections.

References

1. Ferran, A.A., Toutain, P.L., and Bousquet-Mélou, A. *Vet. Microbiol.* **148(2-4)**, 292-297 (2011).
2. Spreng, M., Deleforge, J., Thomas, V., et al. *J. Vet. Pharmacol. Ther.* **18(4)**, 284-289 (1995).
3. Lhermie, G., Ferran, A.A., Assié, S., et al. *Front. Microbiol.* **237(7)**, (2016).
4. Pineda, C., Aguilera-Tejero, E., Morales, M.C., et al. *PLoS One* **12(10)**, e0185981 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/14/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM